CD274 and non-small cell lung carcinoma: Domvanalimab is currently being investigated in several phase III clinical trials: in combination with zimberelimab and chemotherapy for upper gastrointestinal tumors (STAR-221 trial, NCT05568095); with chemotherapy in untreated advanced NSCLC (STAR-121, NCT05502237); and with the anti-PD-L1 durvalumab following concurrent chemoradiotherapy in stage III unresectable NSCLC (PACIFIC-8, NCT05211895), exploring its utility in a curative-intent setting.